Trending Topic

3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
9 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

Denis Poddubnyy, ACR 2021: Secukinumab and HLA Subtypes in AxSpA

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 10th 2021

Prof. Denis Poddubny (Charité-Universitätsmedizin Berlin, Berlin, Germany) kindly took the time to speak with touchIMMUNOLOGY about the post-hoc analysis from the phase 3b SKIPPAIN trial (NCT03136861) aimed at exploring the potential association of HLA-B27 subtypes on the effect of secukinumab in patients with axSpA.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

His presentation entitled Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomised Controlled Trial in Axial SpA(ABSTRACT NUMBER: 0917) was presented at the ACR Convergence, 5-9 November 2021.

Questions

  1. What is known about the association between human leukocyte antigen (HLA) subtypes and axial spondyloarthritis? (0:12)
  2. What were the aims and methodology of this post hoc analysis of the SKIPPAIN trial data? (1:15)
  3. What were the findings of the analysis? (1:40)
  4. What questions remain unanswered about HLA-B27 subtypes and what future studies are planned? (2:17)

Disclosures: Prof. Denis Poddubnyy has received research support from AbbVie, Eli Lilly, MSD, Novartis, and Pfizer; consulting fees from AbbVie, Biocad, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB; and speaker fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, and UCB.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.

Filmed in coverage of virtual ACR Convergence 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup